Polypharmacy, commonly defined as taking five or more medications daily, is a significant health care concern impacting over 30% of older adults. It is associated with poor health outcomes like… read more.
Gilead Sciences, Inc announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November… read more.
Kite, a Gilead Company (Nasdaq: GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood… read more.
NICE (UK): Danicopan (Voydeya) from Alexion/AstraZeneca, is recommended, as an add-on to ravulizumab or eculizumab as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults who have… read more.
Quitting smoking within six months after a cancer diagnosis adds an average of two years to a patient’s life. With this information in hand, all cancer centers have… read more.
Many studies suggest that an earlier age at menopause is more detrimental to a woman’s health, leading to an increased risk for adverse health conditions such as heart disease, diabetes,… read more.
Genentech, a member of the Roche Group, announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH)… read more.
Lundbeck announced that Vyepti (eptinezumab) met the primary and all key secondary endpoints in SUNRISE, a phase III pivotal trial predominantly conducted in Asia evaluating the efficacy and… read more.
Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events: 15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024 Title: Population K-PD Modeling of… read more.
Johnson & Johnson announced that the European Commission (EC) has approved Edurant (rilpivirine) for the treatment of HIV-1 infection in adults and children weighing at least 25 kg… read more.
Edwards Lifesciences Corporation announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is… read more.
The European Medicines Agency (EMA) is revising its ‘competing interests’ policy for experts and members of scientific committees. The new rules are expected to be adopted by the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
